Predicted Level of General Anaesthesia in Hip Fracture Surgery (NAPfem)
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment (Actual)
Enrollment
Phase
Phase
- Phase 4
Contacts and Locations
Study Locations
-
-
-
Angers, France, 49933
- University Hospital Angers
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Patient undergoing hip fracture surgery under general anaesthesia
- Age ≥ 18 years old
- ASA classification 1, 2 or 3
Exclusion Criteria:
- Patient not insured by a social security scheme
- Adult patient under tutorship or curatorship
- Age over 18 years old or under 90 years old
- Weight under 40 or over 140 kilos and/or height under 150 or over 200 cm
- Body mass index > 35
- Contraindication to one or more anaesthetics used in the study
- Pregnancy or breastfeeding
- Unweaned alcoholism
- ASA classification 4 or 5
- Patient undergoing hip fracture surgery under spinal anaesthesia
Study Plan
How is the study designed?
Design Details
- Primary Purpose: SUPPORTIVE_CARE
- Allocation: RANDOMIZED
- Interventional Model: PARALLEL
- Masking: DOUBLE
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Experimental: Smartpilot View group
General anaesthesia managed by the Smartpilot® View device The intervention consists of administering hypnotics and opioids according to effect-site concentrations and interaction model provided by the Smartpilot® View software for the entire duration of general anaesthesia.
|
General anaesthesia managed by the Smartpilot® View device The intervention consists of administering hypnotics and opioids according to effect-site concentrations and interaction model provided by the Smartpilot® View software for the entire duration of general anaesthesia.
|
|
Active Comparator: Control group
General anaesthesia without using the Smartpilot® View device The anesthetic induction will be performed by propofol or sufentanil and atracurium.
The maintenance of anesthesia will be directed by desflurane and sufentanil.
The dosages of anesthetics are left to the discretion of the doctor and nurse anesthetists in charge of the patient in the operating room.
|
General anaesthesia without using the Smartpilot® View device The anesthetic induction will be performed by propofol or sufentanil and atracurium.
The maintenance of anesthesia will be directed by desflurane and sufentanil.
The dosages of anesthetics are left to the discretion of the doctor and nurse anesthetists in charge of the patient in the operating room.
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Percentage of time spent in the "appropriate anaesthesia zone"
Time Frame: participants will be followed for the duration anesthesia, an expected average of 5 hours (from intubation to recovery) for hip fracture surgery
|
The "appropriate anaesthesia zone" is defined as a bispectral index between 45 and 65 and a systolic blood pressure between 80 and 140 mmHg
|
participants will be followed for the duration anesthesia, an expected average of 5 hours (from intubation to recovery) for hip fracture surgery
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Dose of propofol
Time Frame: participants will be followed for the duration anesthesia, an expected average of 5 hours
|
participants will be followed for the duration anesthesia, an expected average of 5 hours
|
|
Dose of sufentanil
Time Frame: participants will be followed for the duration anesthesia, an expected average of 5 hours
|
participants will be followed for the duration anesthesia, an expected average of 5 hours
|
|
Time to extubation
Time Frame: end of anaesthesia
|
end of anaesthesia
|
|
"NASA Task Load Index"
Time Frame: participants will be followed for the duration anesthesia, an expected average of 5 hours
|
participants will be followed for the duration anesthesia, an expected average of 5 hours
|
|
Morphine consumption
Time Frame: participants will be followed for the duration in recovery room, an expected average of 24 hours
|
participants will be followed for the duration in recovery room, an expected average of 24 hours
|
|
Incidence of awareness with recall during anaesthesia
Time Frame: postoperative day 1
|
postoperative day 1
|
|
"Postoperative Quality Recovery Scale"
Time Frame: during recovery room (an expected average of 24 hours) and postoperative days 1 and 3
|
during recovery room (an expected average of 24 hours) and postoperative days 1 and 3
|
|
Length of stay
Time Frame: postoperative day 30
|
postoperative day 30
|
|
Mortality
Time Frame: postoperative day 30
|
postoperative day 30
|
Collaborators and Investigators
Sponsor
Sponsor
Investigators
Investigators
- Principal Investigator: Mathieu CONTE, M.D., University Hospital, Angers
Publications and helpful links
Study record dates
Study Major Dates
Study Start
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Estimate)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- 2014-A01243-44
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.